Market Cap 4.45B
Revenue (ttm) 268.09M
Net Income (ttm) 124.45M
EPS (ttm) N/A
PE Ratio 38.61
Forward PE 41.15
Profit Margin 46.42%
Debt to Equity Ratio 0.00
Volume 168,900
Avg Vol 230,150
Day's Range N/A - N/A
Shares Out 19.94M
Stochastic %K 92%
Beta 1.14
Analysts Strong Sell
Price Target $246.70

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also pr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 7500
Address:
555 Heritage Drive, Suite 200, Jupiter, United States
PriceActionTrader
PriceActionTrader Apr. 18 at 2:49 PM
$LGND Massive structure play setting up here. Weekly breakout from accumulation. Reclaimed Volume POC (~219) = buyers in control. Tight base → expansion move. As long as it holds above value, dips are buyable. Acceptance here → continuation. Lose POC = fake breakout risk. Check
0 · Reply
Doozio
Doozio Apr. 17 at 8:04 PM
$CPRX wen da huckleberries close thru da $$$$ or after they finish up that first base above da $$$$ 🐑 💩 can get $LGND ary it’s textbook ONTO 🐒🍌🧠⏰♾️
1 · Reply
IN0V8
IN0V8 Apr. 15 at 4:21 PM
$LGND Buy Citigroup raises target price to $282 from $276
0 · Reply
Doozio
Doozio Apr. 14 at 8:47 PM
$CPRX 👀s $LGND ary ONTO 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Apr. 14 at 7:15 PM
Wen XBI and IWM lead it gets fookin $LGND ary ONTO 🐒🍌🧠⏰♾️
0 · Reply
Quantumup
Quantumup Apr. 14 at 5:08 PM
Guggenheim⬆️ Best Ideas $TVTX to $54 and reiterated at Buy after the FDA approved Filspari (sparsentan) for focal segmental glomerulosclerosis (FSGS), making it the first and only FDA-approved medicine for FSGS. $LGND $NVS VRTX SNY PFE VERA RHHBY - IONS Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2044099483223409029?s=20
0 · Reply
halabatush
halabatush Apr. 14 at 12:51 PM
Will $LGND follow the same trend of $TVTX?
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 14 at 12:47 PM
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment $TVTX $LGND https://stocktwits.com/news/equity/markets/tvtx-stock-rally-fda-filspari-approval/cZJq5C7RIHm
0 · Reply
DonCorleone77
DonCorleone77 Apr. 14 at 11:14 AM
$LGND $TVTX Ligand partner Travere Therapeutics announces FDA approval for Filspari Ligand (LGND) announced that its partner Travere Therapeutics (TVTX) has received approval from the FDA for Filspari to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis without nephrotic syndrome.
0 · Reply
mikesterz7
mikesterz7 Apr. 14 at 1:14 AM
$TVTX $LGND The FDA approved Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis.
0 · Reply
Latest News on LGND
Ligand to Participate in March Investor Conferences

Mar 4, 2026, 7:00 AM EST - 6 weeks ago

Ligand to Participate in March Investor Conferences


Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Dec 9, 2025, 7:00 AM EST - 4 months ago

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance


Ligand to Participate in November Investor Conferences

Oct 30, 2025, 4:01 PM EDT - 6 months ago

Ligand to Participate in November Investor Conferences


Ligand to Host Investor Day on December 9, 2025

Oct 16, 2025, 7:00 AM EDT - 6 months ago

Ligand to Host Investor Day on December 9, 2025


Ligand to Participate in September Investor Conferences

Aug 19, 2025, 4:00 PM EDT - 8 months ago

Ligand to Participate in September Investor Conferences


Ligand Announces Closing of Convertible Senior Notes Offering

Aug 14, 2025, 4:00 PM EDT - 8 months ago

Ligand Announces Closing of Convertible Senior Notes Offering


Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Jul 10, 2025, 8:00 AM EDT - 10 months ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™


Ligand Announces 2025 Investor Day in New York City

Jun 11, 2025, 7:00 AM EDT - 11 months ago

Ligand Announces 2025 Investor Day in New York City


Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025


Ligand Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 1 year ago

Ligand Reports First Quarter 2025 Financial Results


Ligand to Participate in May Investor Conferences

May 1, 2025, 7:00 AM EDT - 1 year ago

Ligand to Participate in May Investor Conferences


Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ligand to Present at Stifel 2024 Healthcare Conference


Ligand Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Ligand Reports Second Quarter 2024 Financial Results


Ligand to Acquire APEIRON Biologics AG for $100 Million

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Ligand to Acquire APEIRON Biologics AG for $100 Million


Ligand to Participate in Upcoming Investor Conferences

May 23, 2024, 4:59 PM EDT - 2 years ago

Ligand to Participate in Upcoming Investor Conferences


Ligand Reports First Quarter 2024 Financial Results

May 7, 2024, 4:00 PM EDT - 2 years ago

Ligand Reports First Quarter 2024 Financial Results


PriceActionTrader
PriceActionTrader Apr. 18 at 2:49 PM
$LGND Massive structure play setting up here. Weekly breakout from accumulation. Reclaimed Volume POC (~219) = buyers in control. Tight base → expansion move. As long as it holds above value, dips are buyable. Acceptance here → continuation. Lose POC = fake breakout risk. Check
0 · Reply
Doozio
Doozio Apr. 17 at 8:04 PM
$CPRX wen da huckleberries close thru da $$$$ or after they finish up that first base above da $$$$ 🐑 💩 can get $LGND ary it’s textbook ONTO 🐒🍌🧠⏰♾️
1 · Reply
IN0V8
IN0V8 Apr. 15 at 4:21 PM
$LGND Buy Citigroup raises target price to $282 from $276
0 · Reply
Doozio
Doozio Apr. 14 at 8:47 PM
$CPRX 👀s $LGND ary ONTO 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Apr. 14 at 7:15 PM
Wen XBI and IWM lead it gets fookin $LGND ary ONTO 🐒🍌🧠⏰♾️
0 · Reply
Quantumup
Quantumup Apr. 14 at 5:08 PM
Guggenheim⬆️ Best Ideas $TVTX to $54 and reiterated at Buy after the FDA approved Filspari (sparsentan) for focal segmental glomerulosclerosis (FSGS), making it the first and only FDA-approved medicine for FSGS. $LGND $NVS VRTX SNY PFE VERA RHHBY - IONS Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2044099483223409029?s=20
0 · Reply
halabatush
halabatush Apr. 14 at 12:51 PM
Will $LGND follow the same trend of $TVTX?
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 14 at 12:47 PM
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment $TVTX $LGND https://stocktwits.com/news/equity/markets/tvtx-stock-rally-fda-filspari-approval/cZJq5C7RIHm
0 · Reply
DonCorleone77
DonCorleone77 Apr. 14 at 11:14 AM
$LGND $TVTX Ligand partner Travere Therapeutics announces FDA approval for Filspari Ligand (LGND) announced that its partner Travere Therapeutics (TVTX) has received approval from the FDA for Filspari to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis without nephrotic syndrome.
0 · Reply
mikesterz7
mikesterz7 Apr. 14 at 1:14 AM
$TVTX $LGND The FDA approved Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis.
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 14 at 12:34 AM
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease $TVTX $LGND https://stocktwits.com/news/equity/markets/travere-therapeutics-wins-much-awaited-approval-for-drug-in-rare-kidney-disease/cZJpVh1RIu6
0 · Reply
dixiebull
dixiebull Apr. 13 at 10:31 PM
0 · Reply
Doozio
Doozio Apr. 13 at 10:15 PM
$CPSH wen double digits ONTO 🐒🍌🧠⏰. Wen it gets $LGND ary.
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 10 at 1:05 PM
⚠️ BIOTECH BINARY EVENT WEEK 👉Click to view @NasdaqPulse for timely updates amid the volatility. Next week = HIGH RISK / HIGH REWARD setup. Eyes locked on $TVTX into April 13 FDA decision on Filspari (FSGS). This is the kind of catalyst that doesn’t “trend”… it gaps. $LGND quietly in the background — tied to $TVTX via licensing. Sympathy move potential is REAL if outcome surprises. Here’s the trade: ➡️ Pre-event positioning = pure speculation ➡️ Post-decision = follow the FLOW Watch ONE thing above all: price + volume reaction AT the news Not the headline. Not the hype. The reaction. If $TVTX breaks with volume → momentum trade If it fades → liquidity exit This is not investing. This is event trading. Manage risk or get carried out.
1 · Reply
StocktwitsNews
StocktwitsNews Apr. 10 at 11:30 AM
Travere Therapeutics, Ligand In Focus As FDA Set To Rule On Filspari Next Week – First FSGS Drug At Stake $TVTX $LGND https://stocktwits.com/news/equity/markets/travere-tvtx-ligand-lgnd-fda-decision-filspari-fsgs-april-13/cZJ0aQ7RItJ
0 · Reply
Doozio
Doozio Apr. 9 at 6:10 PM
YO $LGCY is gonna be $LGND ary $ONTO 🐒🍌🧠⏰♾️
0 · Reply
JamesTaulman
JamesTaulman Apr. 8 at 2:34 PM
$LGND – Showing Support at the Stacked 10 DMA / the Round-$200 9:10 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/lgnd-showing-support-at-the-stacked-10-dma-the-round-200/?fbclid=IwY2xjawRDRm5leHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEetvEC1bw2AHbi1qGULeH6gKNy_B2eOI9TpFVotxR9aEx09AxPuhOE1G003Mc_aem_ofFb6BQyM-i0SsSee27YdQ
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 3 at 1:40 AM
Our records indicate $PTGX trades at the highest multiple of 5 & 10-year analyst consensus of all commercial-stage bios with market caps over $1B (oncology & non). This is not investment advice. We have no idea if this is a meaningful data point to understand PTGX's value proposition and/or investment thesis. $LGND trades at the 2nd highest (but LGND's gross margin was 95% in FY25). It is worth noting $ZYME is a close third. ZYME's revenues (at least near-term) are sourced via royalties (100% gross margin) just like PTGX For perspective, the attachment compares PTGX's multiples to the 5 we posted last night (appearing on the top). These are traditional comm'l-stage bios responsible for manufacturing & selling their therapies. These are not peers (outside of being biopharmas). $XBI $IBB
1 · Reply
donkeykongreturns
donkeykongreturns Mar. 31 at 3:16 PM
$LGND Big one
0 · Reply
JamesTaulman
JamesTaulman Mar. 28 at 3:19 AM
$LGND – Broke the 50 DMA – Final Sell Signal 09:10 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/lgnd-broke-the-50-dma-final-sell-signal/?fbclid=IwY2xjawQ0J-tleHRuA2FlbQIxMQBicmlkETFXWEhGa2lBTDJFS3lBZnA5c3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHj8ZvXOLZHe0_nLxrSfi_Erel7BzdTqrbL2JLkYc7K8pU5DumcMLfdbjnSSf_aem_qVc3eSVmApq4zgbAIMzEDg
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 27 at 8:46 PM
$LGND RSI: 40.30, MACD: 1.1483 Vol: 5.54, MA20: 206.47, MA50: 197.99 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Mar. 24 at 3:25 PM
Citigroup maintains Ligand Pharmaceuticals $LGND at Buy and raises the price target from $270 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply